SAN FRANCISCO and SUZHOU, China, Oct. 21, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next- generation IO and ADC cancer therapies, with the goal of developing potentially transformative cancer treatments to benefit patients worldwide. This partnership aims to leverage key synergies and accelerate the global development of several investigational medicines within Innovent's IO+ADC pipeline, including: IBI363, ...